Kyowa Hakko Kirin Co Ltd (4151.T)
* Says Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "A+" -R&I
BRIEF-Ultragenyx, Kyowa Hakko Kirin announce submission of Burosumab's Biologics License Application in U.S.
* Ultragenyx and Kyowa Hakko Kirin announce submission of Burosumab's Biologics License Application in the U.S.
* Sumitomo Chemical Co Ltd to buy Kyowa Hakko Kirin's agrochemical segment in deal valued at 6 billion yen to 7 billion yen
BRIEF-Ultragenyx, Kyowa Hakko Kirin, Kyowa Kirin announce positive 24-week data from adult phase 3 study of burosumab
* Ultragenyx, Kyowa Hakko Kirin and Kyowa Kirin International announce positive 24-week data from adult phase 3 study of Burosumab (KRN23) in X-linked hypophosphatemia
* Kyowa Hakko Kirin Co Ltd -announced global phase 3 study of mogamulizumab in patients with cutaneous t-cell lymphoma met its primary endpoint
* Trial did not meet its primary endpoint of progression free survival (pfs).